Samples were mixed at 4C for two hours. Idiopathic inflammatory myositis (IIM) is usually a heterogeneous group of disease that can affect muscles, skin, and lungs. Confirmation of myositis-specific autoantibodies (MSAs) has important implications when diagnosing IIM in patients with high pre-test probability (1). Individuals diagnosed with IIM typically generate one type of MSA. Detection of specific MSA antibodies can guideline clinicians to Palmitoylcarnitine the disease course of a patients subtype of myositis and clinical outcomes (1,2). The presence of anti-MDA5 autoantibodies is usually associated with rapidly progressive interstitial lung disease (ILD), dermatomyositis (DM) associated skin rashes and cutaneous ulceration. Patients typically experience amyopathic or moderate muscle mass disease. In comparison, anti-aminoacyl tRNA synthetase (ARS) antibodies (including Jo1, EJ, KS, PL-7 and PL-12) suggest an increased risk of developing significant interstitial lung disease with the presence of DM-associated skin rashes, Raynauds phenomenon, inflammatory arthritis, mechanics hand and fever. Mi2 autoantibodies suggest the presence of classical dermatomyositis rash with moderate myositis and varying associations of malignancy reported in the literature (1,2). Immunoprecipitation is usually widely considered the reference standard for the detection of myositis autoantibodies. However, the cost, time, and requirement of specialist facilities and staff with expertise in performing and interpreting immunoprecipitation results have limited its common use (3). Utilisation of commercially available immunoassays such as ELISA and immunoblot has increased, but concerns regarding the sensitivity and specificity of these immunoassays in the real world exist (35). Serological screening using ELISA is usually a highly sensitive method for detecting the presence of an MSA; but requires a highly purified recombinant protein. Poor recombinant protein purification, protein expression, and lack of stability increase the risk of false-positive detection of autoantibodies when using ELISA (6). In Japanese cohorts, the sensitivity and specificity of detecting ARS antibodies (PL-12, PL-7, EJ, Jo-1 and KS) when using ELISA compared to IP is usually 97.1% and 99.1%, respectively (7). We have previously reported ELISA as an accurate test for detecting anti-TIF1 with superior sensitivity to blotting-based assays (8). This study aimed to compare the reliability of a commercial ELISA in detecting MSAs compared to immunoprecipitation, the reference standard, in a European populace. MSAs included were anti-Mi2, MDA5, Jo1, EJ, KS, PL-7 and PL-12 from a cohort of adult patients confirmed to have the presence of an MSA on immunoprecipitation. A secondary outcome of this study decided whether using different cut-off points may improve the sensitivity and specificity of the immunoassay in a European population compared to a healthy control populace. == Methods == == Sample selection == Our laboratory has to date, analysed more than 3000 myositis serum samples by immunoprecipitation (2,9). Patients included in this series were all recognized through autoantibody analysis in our laboratory for research or diagnostic purposes. All had been previously screened for autoantibodies by immunoprecipitation, and samples for inclusion were randomly selected from each autoantibody subgroup. Healthy control (HC) samples experienced no known underlying rheumatological condition and were confirmed Palmitoylcarnitine Palmitoylcarnitine to be autoantibody unfavorable by immunoprecipitation. The same serum sample was utilized for both immunoprecipitation and ELISA analysis. Table 1illustrates the number of sera samples with confirmed MSAs and healthy controls used in this study. == Table 1. TM4SF18 == Quantity of sera samples tested on ELISA for both case samples and health controls (HC) and the.